Accumulating evidence suggests that regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC) are elevated in cancer patients and tumor-bearing hosts, and that depletion of Tregs and MDSC may enhance the anti-tumor immunity of the host. Sorafenib, a novel multi-kinase inhibitor, is approved for the treatment of several human cancers, including advanced hepatocellular carcinoma (HCC). Sorafenib is believed to inhibit tumor growth via anti-angiogenesis, cell cycle arrest, and inducing apoptosis. However, the impact of Sorafenib on immune cell populations in tumor-bearing hosts is unclear. In this report, we show that Tregs and MDSC are increased in the spleens and bone marrows of the BALB/c mice with liver hepatoma. The increase in Tregs and MDSC was positively correlated with tumor burden. Treatment of Sorafenib not only inhibited HCC cell growth in mice but also significantly decreased the suppressive immune cell populations: Tregs and MDSC. In conclusion, our study strongly suggests that Sorafenib can enhance anti-tumor immunity via modulating immunosuppressive cell populations in the murine liver cancer model.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Most patients present in late stages of the disease when surgical resection is not feasible, which leads to dismal clinical outcomes. The annual mortality rate is almost equal to the annual incidence, which is approximately 600 000 patients. 1, 2 Radiation therapy and chemotherapy are generally not very effective for HCC. Therefore, developing effective new strategies to target liver cancer is urgently needed. Many studies have investigated immune responses in patients with HCC, [3] [4] [5] [6] and have explored approaches to harness anti-tumor immunity. 3, [7] [8] [9] [10] Immunotherapy for liver cancer has also been actively investigated, and some clinical trials have been reported. 11 Attention has mainly focused on the induction of HCC tumor-specific immunity by introducing tumor-associated antigens (TAAs). [12] [13] [14] Among these TAAs, alpha-fetal protein and glypican-3 have generated significant interest. [15] [16] [17] Both proteins are expressed during embryogenesis, but are silent in most adult tissues. These two proteins are valuable for HCC diagnosis and they have the potential to be target antigens for immunotherapy. Although evidence of immune response to these two antigens in HCC patients has been demonstrated, eliciting anti-tumor immunity using these two antigens is still not robust. [18] [19] [20] [21] One of the potential explanations is that the expression of these two proteins during embryogenesis might have caused immune tolerance in adults. However, it is still unclear how the host immunosurvillence mechanisms interact with HCC to allow tumor to grow. Recently, many studies have suggested the presence of suppressor immune cells that have an important role in immune homeostasis and cancer development/ progression. 22 Several studies, including ours, have shown that development of HCC is associated with a number of immunosuppressive mechanisms. 5, [23] [24] [25] Two groups of cells are implicated as main mediators of immune suppression in cancer: regulatory T cells (Tregs) and regulatory myeloid cells -myeloid-derived suppressor cells (MDSC). MDSC is a heterogeneous population of cells in tumor-bearing mice and cancer patients that have been shown to inhibit T-cell responses. [26] [27] [28] [29] Upregulation of Tregs and MDSC has been demonstrated in patients with HCC. 25, 26, 30 MDSC (identified as CD11b
þ Gr-1 þ cells) have also been shown to accumulate in the spleens, bone marrows, and tumor tissues in tumorbearing mice. 28 It has been suggested that MDSC suppresses specific cellular response to cancer cells. 26 A recent report has also highlighted that MDSC can inhibit NK cells in HCC patients. 30 It is possible that modulation of these cells may offer a new avenue for immunotherapy against cancer. Interestingly, current chemotherapy might already take advantage of this immunoregulatory mechanism. One recent report has shown that the kinase inhibitor, sunitinib, is capable of reversing the accumulation of the suppressive cell populations: MDSC and Tregs, which are potential new mechanisms for this chemotherapy. 31 Sorafenib, another multiple kinase inhibitor, has recently been approved as the first agent for advanced liver cancer therapy. Besides its cell growth inhibitory activity, the precise mechanisms by which Sorafenib suppresses HCC in patients remain to be defined.
To understand the immunoregulation in HCC, to define the mechanisms of therapeutic anti-HCC agents, and to develop more effective immunotherapy, it is essential to have a robust and reliable small-animal model. Genetically engineered mouse models and xenograft liver cancer models are excellent tools to study the intracellular signaling pathways, altered in hepatocarcinogenesis, and to evaluate therapeutic efficacy for anticancer molecules. However, models that can be used for studying immunoregulation in HCC are limited. Recently, Gonzalez-Carmona et al 32 have described an immunocompetent murine model using mouse HCC cell line Hepa129 and the C3H/HeNcrl mice for investigating anti-tumor dendritic cells.
In this report, we describe a robust mouse liver cancer model in a commonly used immunocompetent BALB/c mouse strain. Immune responses and suppressor cells form a complex network in this HCC cancer-bearing mouse model. Moreover, we have shown that Sorafenib is capable of suppressing HCC progression in mice and downregulating Tregs and MDSC, which suggests a novel anti-HCC mechanism in this tumor model.
MATERIALS AND METHODS Tumor Cell Line and Cell Culture
A mouse liver hepatoma cell line BNL 1ME A.7R.1 (referred as 1MEA in this study), was obtained from American Type Culture Collection (ATCC), and maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% heat-inactivated (561C, 30 min) fetal bovine serum (FBS) (GIBCO) and 100 U/ml penicillin, 100 mg/ml streptomycin (Cellgro), L-glutamine (2 mM) in humidified atmosphere of 5% CO 2 at 371C. This tumor cell line was developed from BALB/c mouse. 33 Mice and Tumor Injection BALB/c mice (6-8 weeks of age) were obtained from the Jackson Laboratory. Mice were kept in pathogen-free conditions and handled in accordance with the requirements of the Institutional Guideline for Animal Experiments. The right flanks of BALB/c mice were injected subcutaneously (s.c.) with 5 Â 10 6 1MEA cells in 100 ml of phosphate-buffered saline (PBS). At the end point of the experiments, mice were sacrificed and spleens were collected. Tumors were separated from mice and were measured. Tumor size was indicated as weight (mg). Representative tumor tissues were carefully excised and surface blood was removed by rinsing in cold PBS, then fixed in 10% neutral formalin, and processed for histology staining, or prepared into single cells and stained with fluorescence-conjugated antibodies for flow cytometry analysis.
Flow Cytometric Analysis
Splenic cells were obtained by pressing splenic tissue or lymph node tissue, respectively, through a Nylon Cell Strainer of 40 mm mesh (BD Falcon). Bone marrow cells were collected by flushing femurs and tibias with cold 1 Â PBS in a syringe with a 27-gauge needle. Tumors were prepared as described above to obtain single-cell suspensions. Red blood cells were removed using red blood lysing buffer (Sigma). To decrease nonspecific binding of immunoglobulins, cells were incubated for 30 min with anti-CD16/32 (Fc block). The resulting cells were stained with fluorescence-conjugated antibodies anti-Gr-1, anti-CD11b, anti-CD3, anti-CD4, anti-CD25 (BD Pharmingen), and anti-FOXP3 (eBioscience). After washing with PBS twice, at least 200 000 events were collected and analyzed on a FACSCalibur system with CELLQuest software (Becton Dickinson) for each analysis. The data were expressed as a proportion of positive cells (compared with cells stained with an irrelevant control antibody).
CD11b
þ Cell Functional Assays CD11b þ cells, with purity of more than 90%, were positively selected from splenocytes derived from tumor-free and tumor-bearing mice, by using CD11b microbeads (Miltenyi Biotec), respectively. The CD11b þ -depleted splenocytes were used as responders, and placed in triplicates into a U-bottom 96-well plate (1 Â 10 5 /well), and cocultured with CD11b þ cells (as stimulators) at different ratios in the presence of anti-CD3 (5 mg/ml) for 48 h. At 18 h before collecting, cells were pulsed with [ Sorafenib Treatment In Vivo Sorafenib (Nexavar, 200 mg/tablets) was dissolved in Cremophor EL/95% ethanol (termed as solvent) (50:50; Sigma), prepared stock solution at 6 mg/ml, and stored in À201C for in vivo study. After 2 weeks from tumor cells challenging, mice were divided into two groups (10 mice/ group) and orally fed Sorafenib at 0.6 mg/100 ml/mouse (30 mg/kg, once daily), or 100 ml Cremophor EL/95% ethanol (control group), respectively, by gavage for 2 weeks. At the end point of experiments, mice were killed; tumors and spleens were dissociated and weighed, and femurs and tibias were collected. Splenocytes, bone marrow cells, and single tumor cells were prepared for further analysis.
Immunohistochemistry Analysis of Tumor-Infiltrating Lymphocytes Tumor tissues were immediately removed from the mice following CO 2 asphyxiation and fixed in 10% formalin for 4 h. Subsequent tissue processing, including sectioning and staining, was performed using services provided by the University of Florida's Molecular Pathology and Immunology Core. Briefly, sections obtained through formalin-fixed samples were paraffin-embedded, cut, and collected 100 mm apart, then stained with antibodies to CD4, CD8, and CD25.
To obtain tumor-infiltrating lymphocytes (TIL) from tumors, tumor tissues were cut into small pieces and placed into 40 mm Nylon Cell Strainers in 10 ml cold PBS, and single-cell suspension was prepared by using hub of syringe.
After centrifugation, the resulting cell suspension was washed once in HBSS, resuspended in 5 ml Histopaque-1077 (Sigma), and placed in a sterile 15 ml conical tube, which was centrifuged for 30 min at 3300 r.p.m. at room temperature. The gray layer was collected. After washing with DMEM once, the cells were incubated with 1 ml red blood cell lysis buffer (Sigma) for 5 min at room temperature; subsequently, 25 ml sterile PBS was added to stop the lysis. The cells were washed, counted, and stained with antibodies to CD3, CD4, CD8, and CD25 for flow cytometry analysis.
Statistical Analysis
The statistical significance between values was determined by Student's t-test. All data were expressed as the mean ± s.d. Probability values of Pr0.05 were considered significant. (Figure 1d ). On average, the size of the spleen in a tumor-bearing mouse was three times larger than that of the control mouse (Figures 1e and f) . The size of the spleens was consistent with the number of splenic cells when total splenic cells were counted. Both CD4 and CD8 cells were present in the spleen, and the ratio of CD4/CD8 was not significantly altered. Histologically, there was no significant morphological difference between spleens from the control mice and from the tumor-bearing mice (data not shown). We next examined this population of cells in this animal model. Population of CD11b þ Gr-1 þ MDSC was significantly expanded in tumor-bearing mice (Figures 2c and d) .
RESULTS

Murine Tumor Cell Line Grows and Initiates
To confirm the immunosuppressive activity of these MDSC, we performed cell proliferation assay. As shown in Figure 2e , MDSC inhibited T-cell proliferation.
Sorafenib Inhibits HCC Growth in the Mouse Model Sorafenib has been approved as a systemic therapeutic agent for advanced HCC. Clinical trials indicate that treatment with Sorafenib modestly increases patient survival. 36, 37 To validate the animal model, we tested the effect of Sorafenib on tumor growth. Mice were first injected with 1MEA cells s.c. At 2 weeks after the injection, when the tumor average size is around 0.4 cm, Sorafenib treatment was initiated with daily dose of 30 mg/kg. After 2 weeks of treatment, the mice were sacrificed and tumor sizes were measured. As shown in Figure 3 , Sorafenib significantly inhibited tumor growth; the average tumor size was three times smaller than the control group.
Sorafenib Downregulates Immunosuppressive Cell Population
To further evaluate the mechanisms of Sorafenib inhibition of HCC, we tested the hypothesis whether Sorafenib would exert anti-tumor activity through modulating suppressive populations of the immune cells. 38, 39 We first determined the effect of Sorafenib on CD4 Figure 5 ). By inference, Sorafenib exhibited relative specific activity on Tregs and MDSC.
Lastly, we evaluated for the presence of tumor-infiltrating lymphocytes by using immunohistochemical staining and flow cytometry. Unexpectedly, no significant numbers of CD3, CD4, or CD8 T cells were detected in the tumor tissues (data not shown).
DISCUSSION
There are a number of animal models being used for the study of liver cancer. However, most of the models rely on transgenic and knockout mice. The major disadvantage of these mouse models is the limitation of studying immune regulation because of the immune tolerance developed in these mice. Recently, an immunocompentent mouse model has been described for the study of dendritic cells. 32 There is emerging evidence that immune responses have a significant role in the development and progression of HCC. Thus, a robust mouse model that possesses intact immunity would be a valuable system for the study of HCC.
A murine HCC cell line, 1MEA, was first established two decades ago through chemical carcinogenesis of the immortalized cell line, BNL-derived from a BALB/c mouse. One notable gross finding of the tumor-bearing mice is the enlargement of spleens, which has been noticed in several other cancer murine models. 40, 41 The enlarged spleens suggest the initiation of immune responses to the tumors. The size of the spleens positively correlated with the tumor burdens, as shown in Figure 1 . Extensive evaluation of splenocytes suggests that the splenic enlargement is associated with increased numbers of immune cells, mainly Tregs and MDSC cells. The overall number of CD4 and CD8 cells, and their ratios are not significantly altered. Histologically, there was no distinctive morphological difference between the spleens Liver cancer mouse model M Cao et al taken from normal and tumor-bearing mice. The observation of the splenomegaly in the mice is interesting considering that such phenomenon does not exist in human liver cancer patients.
As our experiments demonstrated, HCC could readily grow in the mice in spite of the robust immune responses. This observation would suggest that specific anti-tumor activity must have been inhibited. We have reported before that human HCC induces an immunosuppressive phenotype, as reflected by the increased circulating Tregs. 25 Recently, another suppressive population of cells MDSC have been shown to be elevated in HCC patients. 26 Therefore, we decided to examine Tregs and MDSC present in the tumorbearing mice. Our data show that both Tregs and MDSC were significantly upregulated in these mice, and they were positively correlated with tumor burden. Moreover, the MDSC cells also exhibited typical suppressive activity when cocultured with effector T cells. We have previously reported At 2 weeks later, the mice with measurable tumor were divided into two groups. Each mouse was gavage-fed with Sorafenib (0.6 mg/100 ml) or solvent (100 ml), once daily, 5 days each week, for 2 weeks. At end point of experiments, mice were sacrificed; tumors and spleens were collected, and weighed. Further experiments will validate these finding using an orthotopic model. The precise mechanism by which Sorefanib influences HCC progression and patient survival is unclear. As it is a kinase inhibitor, one possible mechanism is that it directly induces cancer cell apoptosis or inhibits cancer cell proliferation. Such activity has been reported previously. 42 We tested the in vitro activity of Sorafenib in 1MEA cells and no significant tumor cell death was seen, but there was a significant impact on 1MEA cell proliferation (data not shown). We then tested the effect of Sorafenib in the mouse model. As our data shown in Figure 3 , Sorafenib exhibited overt anti-tumor activity, which is unlikely because of antiproliferation alone. We then examined the possibility of the immunomodulatory effect of Sorafenib in the HCC model. Indeed, the animals treated with the drug exhibited significantly reduced numbers of both Tregs and MSDC. This data suggests an immunomodulatory mechanism of Sorafenib on HCC in vivo. The marked decrease in MDSC from the bone marrow also suggests a direct effect on progenitor cell production, which requires further investigation. One note of caution is that we cannot exclude the possibility of the secondary effect on the suppressive populations, ie, the slow growth of HCC caused by Sorafenib would have less capacity to induce Tregs and MDSC. We believe that both direct and indirect effects may exist in the Sorafenib-treated mice.
There are recent reports about the effect of sunitinib, another kinase inhibitor, on the inhibition of MDSC. 31 OzaoChoy et al 38 hypothesized that malate, a receptor tyrosine kinase inhibitor, could reverse MDSC-mediated immune suppression and modulate the tumor microenvironment, thereby improving the efficacy of immune-based therapies. Treatment with sunitinib decreased the number of MDSC and Treg in advanced tumor-bearing animals. Furthermore, it not only reduced the suppressive function of MDSC but also prevented tumor-specific T-cell anergy and Treg development. Interestingly, sunitinib treatment resulted in 44 In many rodent tumor models, the mobilization of T-cell responses is also sufficient to eradicate tumors early during their establishment. 45, 46 However, such mobilization is clearly less effective when it occurs late during tumor progression, in both rodent tumor models and in human cancer patients. 47, 48 Studies suggested an inability of functionally normal T cells to infiltrate or persist in late-stage solid tumors because of physical barriers and/or emigration from the tumor site. 48, 49 In our study, we did not detect significant infiltration of T cells in the tumor tissues. The reason may be partially because of late stage of tumor progression or the ectopic nature of the tumor.
In summary, we have established a novel, immunocompetent HCC mouse model that demonstrates the relevance to human HCC. Using this model, we have studied the immune response to HCC and examined the treatment effect of kinase inhibitor, Sorafenib. Our results show that HCC can upregulate immunosuppressive population of cells: Tregs and MDSC. We also found that Sorefanib modulated immune responses by suppressing Tregs and MDSC. We believe that this validated model can be used for understanding the immunoregulations in HCC, immunotherapy, and evaluating novel therapeutic agents.
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